Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide

Postgrad Med J. 1995 Apr;71(834):229-30. doi: 10.1136/pgmj.71.834.229.

Abstract

The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Neoplasms / complications*
  • Cushing Syndrome / drug therapy*
  • Female
  • Humans
  • Hydrocortisone / urine
  • Middle Aged
  • Octreotide / therapeutic use*
  • Palliative Care
  • Testosterone / blood
  • Time Factors
  • Treatment Outcome

Substances

  • Testosterone
  • Octreotide
  • Hydrocortisone